RT @DrBaileeSliker: Want more from Chris Jones after his keynote lecture at @chadtough this morning? Check out one of his recent @CD_AACR p…
RT @DrBaileeSliker: Want more from Chris Jones after his keynote lecture at @chadtough this morning? Check out one of his recent @CD_AACR p…
Want more from Chris Jones after his keynote lecture at @chadtough this morning? Check out one of his recent @CD_AACR papers on repurposing Vandetanib for the treatment of ACVR1-mutant #DIPG https://t.co/73Jdc0IiSn https://t.co/Qxbp2ZWney
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
RT @DrBaileeSliker: #AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment o…
#AACR23 Advances in Brain Tumor Treatment ICYMI in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma @diana_mcarvalho @ICR_London @royalmarsdenNHS #DIPG #ArtificialIntelligence https://t.co/
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
RT @CD_AACR: From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine gl…
From the February issue: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma by C. Jones, Carceller, @diana_mcarvalho et al. https://t.co/3H98dYzePz @ICR_London @royalmarsdenNHS #DIPG #ArtificialIntel
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma [Research Articles] https://t.co/UZvP9iayD5
RT @EANOassociation: Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma https://t.co…
RT @EANOassociation: Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma https://t.co…
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma https://t.co/HX9cK8NY18 #btsm
RT @NatRevClinOncol: VEGFR/RET/EGFR TKI vandetanib found to target ACVR1, which is mutated in 25% of children with DIPG, with everolimus…
RT @NatRevClinOncol: VEGFR/RET/EGFR TKI vandetanib found to target ACVR1, which is mutated in 25% of children with DIPG, with everolimus…
RT @NatRevClinOncol: VEGFR/RET/EGFR TKI vandetanib found to target ACVR1, which is mutated in 25% of children with DIPG, with everolimus…
VEGFR/RET/EGFR TKI vandetanib found to target ACVR1, which is mutated in 25% of children with DIPG, with everolimus synergizing in inhibiting DIPG cell growth in vitro. This combination improved outcomes in an orthotopic PDX model of ACVR1-mutant DIPG: h
RT @OncoViews: Using an AI-based platform, #verolimus + #vandetanib has been identified as a therapeutic approach for ACVR1-mutant #DIPG.…
RT @OncoViews: Using an AI-based platform, #verolimus + #vandetanib has been identified as a therapeutic approach for ACVR1-mutant #DIPG.…
RT @OncoViews: Using an AI-based platform, #verolimus + #vandetanib has been identified as a therapeutic approach for ACVR1-mutant #DIPG.…
Using an AI-based platform, #verolimus + #vandetanib has been identified as a therapeutic approach for ACVR1-mutant #DIPG. Check out the article by @diana_mcarvalho and colleagues from @ICR_London, @royalmarsdenNHS, and @benevolent_ai in @CD_AACR ⬇️ http
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma https://t.co/CsRDcptjoS
RT @CD_AACR: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. https://t.co/XbsHO6…
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. https://t.co/XbsHO69Npo. @ICR_London @RobinL_Jones. #DIPG #ArtificialIntelligence https://t.co/SC79d0ZoX1
RT @EmilianPath: #AI #cancer #research Using an Artificial Intelligence-based platform to search for approved compounds for ACVR1-mutant DI…
Impressive collaboration @ICR_London @royalmarsdenNHS @benevolent_ai using AI to identify a drug combination to target a rare childhood cancer @CD_AACR https://t.co/DE6N3fPYUf also super interesting #polypharmacoloy leading to efficacy: Vandetanib-ACVR1
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma https://t.co/nhbjnw8RCv
@shitscaredmum @AbbiesArmy The link in the article did not work for me. Nevertheless, I found the referenced paper. Thanks! #BTSM https://t.co/wic095ay8B
RT @ElizSMcKenna: Now online in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontin…
Now online in @CD_AACR: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma @ICR_London @royalmarsdenNHS #DIPG #ArtificialIntelligence https://t.co/jRx58yzDrc
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma https://t.co/h9sdldiuZg
You can read the study in full via Cancer Discovery. https://t.co/XbtS5vOCf8
#AI #cancer #research Using an Artificial Intelligence-based platform to search for approved compounds for ACVR1-mutant DIPG, the combination of vandetanib and everolimus was identified as a possible therapeutic approach. https://t.co/QQmf1h5A9k